Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
pharmaphorum5y
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe
Two biosimilars of Eli Lilly’s blockbuster osteoporosis treatment Forsteo – from Hungary’s Gedeon Richter and German partner Stada – have made their debut in Europe. Forsteo (teriparatide ...
Medscape10d
The Cost Effectiveness of Teriparatide as a First-line Treatment for Glucocorticoid-induced and Postmenopausal Osteoporosis Patients in Sweden
Background: This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced ...